• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Windtree touts preclinical data from influenza study for aerosolized surfactant

February 16, 2017 By Sarah Faulkner

Windtree TherapeuticsWindtree touts preclinical data for aerosolized surfactant (NSDQ:WINT) said today that a preclinical influenza study demonstrated that its aerosolized KL4 surfactant reduced lung inflammation and improved overall survival in ferrets.

In the preclinical study, researchers compared Windtree’s aerosolized KL4 surfactant with a daily oral dose of oseltamivir, an antiviral, and placebo controls. Following exposure to the influenza virus, investigators evaluated the ferrets for clinical signs of infection and lung histopathology changes.

“While we remain focused on the rigorous and timely execution of the Aerosurf phase II clinical program in premature infants with respiratory distress syndrome, we are encouraged by the results of this study in influenza as there is significant unmet need to protect the lungs in patients with severe influenza pneumonia,” president & CEO Craig Fraser said in prepared remarks. “A Phase I SBIR contract from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health provided us the opportunity to study the use of KL4 surfactant to reduce lung injury after exposure to a highly pathogenic influenza strain. We are grateful for the support provided by the NIH for this study as well as the previously announced preclinical study in the use of KL4 surfactant as a medical countermeasure to mitigate damage to lungs after radiation exposure. Windtree plans to seek additional funding from the NIH to support further exploration of aerosolized KL4 surfactant as a potential medical countermeasure for treating influenza-associated lung injury.”

Analysis of the study’s data showed that treatment with Windtree’s KL4 surfactant substantially improved survival and reduced lung injury from influenza infection both at day 5 and day 14. Animals that were treated with Kl4 surfactant or oseltamivir had survival ratings of 80%, while the animals in the control arm had a 20% survival rate.  

The KL4 group had fewer clinical signs of influenza compared to the oseltamivir group, Windtree reported.

“Though this is an early proof-of-concept study of aerosolized KL4 surfactant for treatment of a lethal flu strain, these data are especially encouraging as the NIH has stated that there is an urgent need to develop new therapeutic candidates that have the potential to prevent severe life-threatening complications of human influenza, improve patient outcomes, and provide more and better options for monotherapy and combination therapy with existing antivirals,” senior VP of clinical development and academic affairs, Dr. Robert Segal, added. “These data represent progress toward a potentially effective and efficient therapeutic to prevent lung injury associated with influenza, particularly when highly lethal, pandemic strains are involved.”

Filed Under: Featured, Pharmaceuticals, Preclinical Trials, Wall Street Beat Tagged With: Windtree Therapeutics

IN CASE YOU MISSED IT

  • Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent
  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS